Skip to main content
Log in

15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson’s disease patient with Parkin gene mutation: a case report

  • Brief Communication
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Introduction

Parkinson’s Disease (PD) patients with Parkin gene (PRKN) mutations show good response to subthalamic deep brain stimulation (STN-DBS). Currently, the longest follow-up available of these patients is 6 years. We report a very long-term outcome (more than 15 years) of a STN-DBS-treated patient with a compound heterozygous deletion of exons 3 and 11 of the PRKN gene.

Case report

In 1993, a 39-year-old male was diagnosed with PD after the onset of resting tremor. Levodopa was started, and during the following 10 years, he reported good motor symptoms control, with only mild modification of levodopa intake and pramipexole introduction. In 2005, he developed disabling motor fluctuations and dyskinesia. In 2007, he underwent bilateral STN-DBS, with a marked improvement of motor symptoms and fluctuations during the following years. After 6 years, he reported mild motor fluctuations, improved after stimulation and treatment modifications. After 10 years he showed diphasic dyskinesias, feet dystonia, postural instability, and gambling (resolved after pramipexole discontinuation). In 2018, he developed a non-amnestic single-domain mild cognitive impairment (MCI). In 2023, after more than 15 years of STN-DBS, motor symptoms and fluctuations are still well controlled. He reports mild dysphagia, mild depression, and multiple-domain MCI. His quality of life is better than before surgery, and he still reports a subjective significant improvement from STN-DBS.

Conclusion

Confirming the very long-term efficacy of STN-DBS in PRKN-mutated patients, our case report underlines their peculiar suitability for surgical treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Kasten M, Hartmann C, Hampf J et al (2018) Genotype-phenotype relations for the Parkinson’s disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord 33:730–741. https://doi.org/10.1002/mds.27352

    Article  PubMed  Google Scholar 

  2. Lunati A, Lesage S, Brice A (2018) The genetic landscape of Parkinson's disease. Rev Neurol (Paris) 174:628–643. https://doi.org/10.1016/j.neurol.2018.08.004

    Article  CAS  PubMed  Google Scholar 

  3. Wasner K, Grünewald A, Klein C (2020) Parkin-linked Parkinson's disease: from clinical insights to pathogenic mechanisms and novel therapeutic approaches. Neurosci Res 159:34–39. https://doi.org/10.1016/j.neures.2020.09.001

    Article  CAS  PubMed  Google Scholar 

  4. Artusi CA, Dwivedi AK, Romagnolo A et al (2019) Association of Subthalamic Deep Brain Stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease: a systematic review and meta-analysis. JAMA Netw Open 2:e187800. https://doi.org/10.1001/jamanetworkopen.2018.7800

    Article  PubMed  PubMed Central  Google Scholar 

  5. Moro E, Volkmann J, König IR et al (2008) Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 70:1186–1191. https://doi.org/10.1212/01.wnl.0000307748.11216.03

    Article  CAS  PubMed  Google Scholar 

  6. Goetz CG, Stebbins GT, Tilley BC (2012) Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord 27:1239–1242. https://doi.org/10.1002/mds.25122

    Article  PubMed  Google Scholar 

  7. Dalrymple-Alford JC, MacAskill MR, Nakas CT et al (2011) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75:1717–1725. https://doi.org/10.1212/WNL.0b013e318219dc77

    Article  Google Scholar 

  8. Martínez-Martín P, Rodríguez-Blázquez C, Alvarez M et al (2015) Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord 21:50–54. https://doi.org/10.1016/j.parkreldis.2014.10.026

    Article  PubMed  Google Scholar 

  9. Bove F, Mulas D, Cavallieri F et al (2021) Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology 97:e254–e262. https://doi.org/10.1212/WNL.0000000000012246

    Article  Google Scholar 

  10. Merola A, Romagnolo A, Dwivedi AK et al (2020) Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. J Neurol 267:2949–1960. https://doi.org/10.1007/s00415-020-09954-6

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank our patient and his family for their consent for publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alberto Romagnolo.

Ethics declarations

Ethical approval

The authors confirm that the approval of an institutional review board was not required for this work.

Consent for publication

Oral and written informed consent were obtained from the patient for publication of this case.

Conflict of Interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Covolo, A., Imbalzano, G., Artusi, C.A. et al. 15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson’s disease patient with Parkin gene mutation: a case report. Neurol Sci 44, 2939–2942 (2023). https://doi.org/10.1007/s10072-023-06789-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-023-06789-7

Keywords

Navigation